KR102359143B1 - 헤테로시클릭 화합물 - Google Patents

헤테로시클릭 화합물 Download PDF

Info

Publication number
KR102359143B1
KR102359143B1 KR1020217019537A KR20217019537A KR102359143B1 KR 102359143 B1 KR102359143 B1 KR 102359143B1 KR 1020217019537 A KR1020217019537 A KR 1020217019537A KR 20217019537 A KR20217019537 A KR 20217019537A KR 102359143 B1 KR102359143 B1 KR 102359143B1
Authority
KR
South Korea
Prior art keywords
group
substituted
compound
cancer
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217019537A
Other languages
English (en)
Korean (ko)
Other versions
KR20210092301A (ko
Inventor
다카하루 히라야마
요시테루 이토
히로시 반노
히데카즈 도쿠하라
도시오 다나카
야스요시 아리카와
노리유키 니이
요우이치 가와키타
신이치 이마무라
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Priority to KR1020227003334A priority Critical patent/KR102646470B1/ko
Publication of KR20210092301A publication Critical patent/KR20210092301A/ko
Application granted granted Critical
Publication of KR102359143B1 publication Critical patent/KR102359143B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
KR1020217019537A 2018-11-28 2019-11-27 헤테로시클릭 화합물 Active KR102359143B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227003334A KR102646470B1 (ko) 2018-11-28 2019-11-27 헤테로시클릭 화합물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018222530 2018-11-28
JPJP-P-2018-222530 2018-11-28
PCT/JP2019/046261 WO2020111087A1 (ja) 2018-11-28 2019-11-27 複素環化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003334A Division KR102646470B1 (ko) 2018-11-28 2019-11-27 헤테로시클릭 화합물

Publications (2)

Publication Number Publication Date
KR20210092301A KR20210092301A (ko) 2021-07-23
KR102359143B1 true KR102359143B1 (ko) 2022-02-08

Family

ID=70853784

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227003334A Active KR102646470B1 (ko) 2018-11-28 2019-11-27 헤테로시클릭 화합물
KR1020217019537A Active KR102359143B1 (ko) 2018-11-28 2019-11-27 헤테로시클릭 화합물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020227003334A Active KR102646470B1 (ko) 2018-11-28 2019-11-27 헤테로시클릭 화합물

Country Status (16)

Country Link
US (4) US12152027B2 (enExample)
EP (1) EP3888652A4 (enExample)
JP (2) JP6972384B2 (enExample)
KR (2) KR102646470B1 (enExample)
CN (2) CN113038948B (enExample)
AU (1) AU2019390863B2 (enExample)
BR (1) BR112021009994A2 (enExample)
CA (1) CA3120774A1 (enExample)
IL (2) IL283368B2 (enExample)
MX (2) MX2021005877A (enExample)
MY (1) MY209902A (enExample)
PH (1) PH12021551251A1 (enExample)
SG (1) SG11202105652XA (enExample)
TW (3) TW202438498A (enExample)
WO (1) WO2020111087A1 (enExample)
ZA (1) ZA202104402B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283368B2 (en) * 2018-11-28 2025-01-01 Takeda Pharmaceuticals Co Imidazo[2,1-b]pyridazin-7-yl urea compound and medicament containing the compound
JP7672402B2 (ja) * 2020-05-27 2025-05-07 武田薬品工業株式会社 複素環化合物の製造方法
AU2021361057A1 (en) * 2020-10-16 2023-06-08 Rarefied Biosciences, Inc. Malt1 modulators and uses thereof
GB202018412D0 (en) 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
JP2025501056A (ja) 2021-12-30 2025-01-17 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 三環系誘導体阻害剤、その製造方法と応用
JPWO2023149450A1 (enExample) 2022-02-02 2023-08-10
WO2025123039A1 (en) * 2023-12-08 2025-06-12 Shaman Pharma, LLC Method for Production of Spiro-Oxindole and Indoxyl Derivatives of Mitragynine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015181747A1 (en) 2014-05-28 2015-12-03 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
WO2017081641A1 (en) 2015-11-13 2017-05-18 Novartis Ag Novel pyrazolo pyrimidine derivatives
WO2018020474A1 (en) 2016-07-29 2018-02-01 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
WO2018165385A1 (en) 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2288521A1 (fr) 1974-10-25 1976-05-21 Merck Patent Gmbh Nouvelles penicillines et procede pour leur preparation
WO1996038445A1 (en) * 1995-05-31 1996-12-05 Sumitomo Pharmaceuticals Company, Limited Novel naphthyridine derivatives
GB9720052D0 (en) * 1997-09-19 1997-11-19 Smithkline Beecham Plc Novel compounds
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
WO2018085247A1 (en) * 2016-11-01 2018-05-11 Cornell University Compounds for malt1 degradation
US20200111087A1 (en) * 2018-10-08 2020-04-09 Jinlei Zhou Method for encrypting digital contract document between contractors
IL283368B2 (en) * 2018-11-28 2025-01-01 Takeda Pharmaceuticals Co Imidazo[2,1-b]pyridazin-7-yl urea compound and medicament containing the compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015181747A1 (en) 2014-05-28 2015-12-03 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
WO2017081641A1 (en) 2015-11-13 2017-05-18 Novartis Ag Novel pyrazolo pyrimidine derivatives
WO2018020474A1 (en) 2016-07-29 2018-02-01 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
WO2018165385A1 (en) 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof

Also Published As

Publication number Publication date
MX2024003064A (es) 2024-03-27
TWI784213B (zh) 2022-11-21
SG11202105652XA (en) 2021-06-29
TW202039484A (zh) 2020-11-01
KR20210092301A (ko) 2021-07-23
CA3120774A1 (en) 2020-06-04
JPWO2020111087A1 (ja) 2021-09-27
IL283368A (en) 2021-07-29
EP3888652A4 (en) 2022-10-19
CN113038948B (zh) 2024-07-12
IL303962A (en) 2023-08-01
US20220048916A1 (en) 2022-02-17
WO2020111087A1 (ja) 2020-06-04
JP6972384B2 (ja) 2021-11-24
JP2022017461A (ja) 2022-01-25
CN118420620A (zh) 2024-08-02
US12152027B2 (en) 2024-11-26
PH12021551251A1 (en) 2021-12-06
US11897879B2 (en) 2024-02-13
IL283368B1 (en) 2024-09-01
TWI848400B (zh) 2024-07-11
KR102646470B1 (ko) 2024-03-11
MY209902A (en) 2025-08-09
US20250034141A1 (en) 2025-01-30
EP3888652A1 (en) 2021-10-06
JP7434249B2 (ja) 2024-02-20
AU2019390863A2 (en) 2021-07-01
CN113038948A (zh) 2021-06-25
ZA202104402B (en) 2023-01-25
AU2019390863A1 (en) 2021-06-24
WO2020111087A9 (ja) 2021-01-21
AU2019390863B2 (en) 2025-02-20
BR112021009994A2 (pt) 2021-08-17
US11230545B2 (en) 2022-01-25
MX2021005877A (es) 2021-07-16
TW202306956A (zh) 2023-02-16
US20220089595A1 (en) 2022-03-24
NZ777412A (en) 2024-05-31
TW202438498A (zh) 2024-10-01
US20210332045A1 (en) 2021-10-28
KR20220019848A (ko) 2022-02-17
IL283368B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
KR102359143B1 (ko) 헤테로시클릭 화합물
AU2018272013B2 (en) Crystalline forms of a FGFR inhibitor and processes for preparing the same
CA3157361A1 (en) Bicyclic heterocycles as fgfr inhibitors
JP5490030B2 (ja) 縮合複素環誘導体およびその用途
WO2024015731A1 (en) Fused tricyclic compounds as inhibitors of kras g12v mutants
JP6924182B2 (ja) 縮合複素環化合物
RU2808435C2 (ru) Гетероциклическое соединение
US10774083B2 (en) Heterocyclic amide compound
HK40051951A (zh) 杂环化合物
TWI862653B (zh) 雜環化合物
HK40051951B (zh) 杂环化合物
HK40072079A (en) Heterocyclic compound

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5